Jonathan Piazza - 01 Feb 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role
Chief Financial Officer
Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
02 Feb 2022, 16:19:53 UTC
Next filing
04 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Award $0 +11,250 +79% $0.000000 25,534 01 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +67,500 $0.000000 67,500 01 Feb 2022 Common Stock 67,500 $4.85 Direct F3
transaction SPRY Stock Option (right to buy) Award $0 +42,750 $0.000000 42,750 01 Feb 2022 Common Stock 42,750 $4.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 2,054 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2021 and 326 shares acquired under the ESPP on December 31, 2021.
F3 The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
F4 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.